Stock Price & Analysis

Based on the analysis of EXAS stock, it is currently showing mixed signals. The stock has a low RSI of 23.67, suggesting it may be oversold, but analyst opinions are divided, with some raising targets and others lowering them. Given the mixed signals and current market position, it may be wise to hold or consider selling if you are risk-averse.

Price Prediction for EXAS Stock in 2025

Based on current trends and analyst adjustments, EXAS stock is predicted to reach $50 by the end of 2025. This forecast considers the recent price target adjustments by Piper Sandler (lowered to $70) and Scotiabank (raised to $73), reflecting mixed analyst sentiment.

The stock's technical indicators, such as RSI and MACD, suggest a bearish trend, but the company's strong product portfolio, including Cologuard, positions it for potential recovery.

The S1 support level for EXAS Stock is $43.16 ,The R1 resistant level for EXAS Stock is $49.35.

As of the end of day on 2025-03-14, the price of EXAS Stock was $43.83.

The target price for EXAS Stock according to analyst rating is 72.57, with the highest price target at 86.00 and the lowest at 65.00. Analysts have a Strong Buy rating on EXAS Stock overall.

The market cap of EXAS is $8.0B.

Analysis and Insights

EXAS may be overvalued based on its high valuation multiples and mixed analyst sentiment.

1. Valuation Metrics: EXAS has an EV/EBITDA of 49.02 and a PS ratio of 3.93, both above industry averages, suggesting premium pricing relative to earnings and revenue.

2. Analyst Sentiment: While Scotiabank raised its price target to $73, Piper Sandler lowered it to $70, reflecting mixed outlooks on growth potential.

3. Technical Indicators: The stock is oversold with an RSI of 30.27, but its high EV/EBITDA ratio indicates overvaluation compared to peers.

4. Fibonacci Levels: The Fibonacci pivot at $47.82 suggests resistance, limiting near-term upside.

5. Conclusion: EXAS appears overvalued fundamentally due to high multiples, but technical indicators and analyst targets suggest potential upside.

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

EXAS stock is predicted to reach $80 by 2030, driven by strong revenue growth and new product launches.

EXAS has a total of 6500 employees.